(Q36342985)

13 August 2017

1 reference

title

Pharmacogenetics of antihypertensive treatment (English)

1 reference

13 August 2017

1

Donna K Arnett

1 reference

13 August 2017

Steven A Claas

2

1 reference

13 August 2017

Stephen P Glasser

series ordinal

3

1 reference

13 August 2017

publication date

13 December 2005

1 reference

13 August 2017

published in

Vascular Pharmacology

1 reference

13 August 2017

volume

44

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

107-118

1 reference

Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Amiloride, a specific drug for hypertension in black people with T594M variant?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Genetic polymorphisms of the beta-adrenergic system: association with essential hypertension and response to beta-blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal D

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Association of the G(s)alpha gene with essential hypertension and response to beta-blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Effects of Antihypertensive Drugs and Gene Variants in the Renin-Angiotensin System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Worldwide prevalence of hypertension: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Correlation of Angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by Angiotensin-converting enzyme inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Gly389Arg polymorphism of β1-adrenergic receptor is associated with the cardiovascular response to metoprolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Genomic organization of ATOX1, a human copper chaperone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Effect of the C825T polymorphism of the G protein beta 3 subunit on the systolic blood pressure-lowering effect of clonidine in young, healthy male subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Variants of the CYP11B2 gene predict response to therapy with candesartan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Genomics and hypertension: concepts, potentials, and opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

ACE and α-Adducin Polymorphism as Markers of Individual Response to Diuretic Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Impact of ACE polymorphism on renal allograft function, blood pressure, and proteinuria under ACE inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Effects of endothelial nitric oxide synthase, α-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Pharmacogenomics: bench to bedside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Relationship between polymorphism of the angiotensin-converting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

D919G polymorphism of methionine synthase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.09.010

10.1016/J.VPH.2005.09.010

7 January 2021

Identifiers

DOI

1 reference

13 August 2017

1 reference